Astrazeneca (AZN) Assets Average (2009 - 2026)

Astrazeneca has reported Assets Average for 18 years, with the latest figure at $114.9 billion in Q2 2026.

• On a quarterly basis, Assets Average rose 5.11% year-over-year to $114.9 billion in Q2 2026; TTM through Jun 2026 was $114.9 billion, a 5.11% increase from a year earlier, with the FY2025 full-year figure at $109.1 billion, up 6.31% from the prior year.
• Assets Average was $114.9 billion for Q2 2026 at Astrazeneca, up from $114.0 billion in the prior quarter.
• The five-year high for Assets Average was $114.9 billion in Q2 2026, with the low at $95.3 billion in Q4 2022.
• Average Assets Average over 5 years is $103.6 billion, with a median of $103.1 billion recorded in 2022.
• The largest YoY upside for Assets Average was 56.19% in 2022 against a maximum downside of 10.31% in 2022.
• Over 5 years, Assets Average stood at $95.3 billion in 2022, then increased by 3.43% to $98.6 billion in 2023, then increased by 5.96% to $104.5 billion in 2024, then increased by 9.37% to $114.3 billion in 2025, then climbed by 0.58% to $114.9 billion in 2026.
• The last three Assets Average figures came in at $114.9 billion (Q2 2026), $114.0 billion (Q1 2026), and $114.3 billion (Q4 2025), per Business Quant data.